IP Library Granted Patent US 10,238,640
Granted Patent B2
US 10,238,640 · App. 15/349,101 · Granted Mar 26, 2019

Pharmaceutical suspension composition

Inventors: Jay Dickerson (Midlothian, VA); William Mark (Glen Allen, VA); Annabelle Trimmer (Manakin-Sabot, VA); David Jaeger (Chester, VA); Amanda Alley (Midlothian, VA)
Assignee: Wyeth LLC
A61K31/4402A61K9/0053A61K9/0095A61K9/10A61K31/00A61K31/137A61K31/192A61K45/06A61K47/10A61K47/12A61K47/183A61K47/26A61K47/36A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,640
App. No.
15/349,101
Granted
Mar 26, 2019
Kind
B2
Abstract

An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.

Claims (3)

1. A thixotropic oral liquid pharmaceutical composition consisting of 0.2 g/100 mL xanthan gum; 1.5 g/100 mL microcrystalline cellulose/carboxymethylcellulose sodium; about 2 g/100 mL ibuprofen; about 28.8 g/100 mL glycerin; 20 g/100 mL sorbitol solution 70%; about 0.2 g/100 mL sucralose; 0.3 g/100 mL polysorbate; about 0.02 g/100 mL chlorpheniramine maleate; about 0.3 g/100 mL pseudoephedrine; about 0.55 g/100 mL sodium citrate; about 0.25 g/100 mL sodium benzoate; about 0.05 g/100 mL edetate disodium; about 0.75 g/100 mL citric acid; flavoring agent; coloring agent; and water.

2. A thixotropic oral liquid pharmaceutical composition consisting of about 2 g/100 mL ibuprofen; 0.2 g/100 mL xanthan gum; 1.5 g/100 mL microcrystalline cellulose/carboxymethylcellulose sodium; about 28.8 g/100 mL glycerin; 20 g/100 mL sorbitol solution 70%; about 0.55 g/100 mL sodium citrate; about 0.05 g/100 mL edetate disodium; about 0.75 g/100 mL citric acid; 0.3 g/100 mL polysorbate; about 0.25 g/100 mL sodium benzoate; about 0.2 g sucralose/100 mL; flavoring agent; and water.

3. A thixotropic oral liquid pharmaceutical composition consisting of 0.2 g/100 mL xanthan gum; about 1.5 g/100 mL microcrystalline cellulose/carboxymethylcellulose sodium; about 1 g/100 mL to about 3 g/100 mL ibuprofen; 0.3 g/100 mL polysorbate; about 0.25 g/100 mL sodium benzoate; about 0.01 g/100 mL to about 0.40 g/100 mL diphenhydramine; about 28.8 g/100 mL glycerin; about 20 g/100 mL sorbitol solution 70%; sucralose; about 0.55 g/100 mL sodium citrate; about 0.05 g/100 mL edetate disodium; about 0.75 g/100 mL citric acid; flavoring agent; and water.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Apr 6, 2022
From: PF CONSUMER HEALTHCARE 1 LLC; GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 059620/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: WYETH LLC
To: PF CONSUMER HEALTHCARE 1 LLC
Reel/Frame 050727/0184 →
ARTICLES OF ORGANIZATION-CONVERSION Recorded Feb 23, 2018
From: WYETH
To: WYETH LLC
Reel/Frame 045425/0578 →
Continuity (4)
Continuation 14165887 · Jan 28, 2014
Continuation 12403081 · Mar 12, 2009
Division 10852946 · May 25, 2004
Related Publication 20170065567A1 · Mar 9, 2017
Cited By (1)
US 12,629,422